WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

ATC level alterations

Previous ATC codeATC level nameNew ATC code
L01XY02pertuzumab and trastuzumabL01FY01
L01XY03nivolumab and relatlimabL01FY02
L04AA27fingolimodL04AE01
L04AA38ozanimodL04AE02
L04AA42siponimodL04AE03
L04AA50ponesimodL04AE04
L04AA29tofacitinibL04AF01
L04AA37baricitinibL04AF02
L04AA44upadacitinibL04AF03
L04AA45filgotinibL04AF04
L04AA46itacitinibL04AF05
L04AA49peficitinibL04AF06
L04AA56deucravacitinibL04AF07
L04AA02muromonab-CD3L04AG01
L04AA21efalizumabL04AG02
L04AA23natalizumabL04AG03
L04AA26belimumabL04AG04
L04AA33vedolizumabL04AG05
L04AA34alemtuzumabL04AG06
L04AA35begelomabL04AG07
L04AA36ocrelizumabL04AG08
L04AA39emapalumabL04AG09
L04AA47inebilizumabL04AG10
L04AA51anifrolumabL04AG11
L04AA52ofatumumabL04AG12
L04AA53teprotumumabL04AG13
L04AA57ublituximabL04AG14
L04AA10sirolimusL04AH01
L04AA18everolimusL04AH02
L04AA25eculizumabL04AJ01
L04AA43ravulizumab L04AJ02
L04AA54pegcetacoplanL04AJ03
L04AA55sutimlimabL04AJ04
L04AA59avacopanL04AJ05
L04AA13leflunomideL04AK01
L04AA31teriflunomideL04AK02
N05CM19suvorexantN05CJ01
N05CM21lemborexantN05CJ02

Last updated: 2023-12-15